Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design.

Trail PA, Dubowchik GM, Lowinger TB.

Pharmacol Ther. 2018 Jan;181:126-142. doi: 10.1016/j.pharmthera.2017.07.013. Epub 2017 Jul 27. Review.

PMID:
28757155
2.

A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy.

Yurkovetskiy AV, Yin M, Bodyak N, Stevenson CA, Thomas JD, Hammond CE, Qin L, Zhu B, Gumerov DR, Ter-Ovanesyan E, Uttard A, Lowinger TB.

Cancer Res. 2015 Aug 15;75(16):3365-72. doi: 10.1158/0008-5472.CAN-15-0129. Epub 2015 Jun 25.

3.

Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.

Walsh MD, Hanna SK, Sen J, Rawal S, Cabral CB, Yurkovetskiy AV, Fram RJ, Lowinger TB, Zamboni WC.

Clin Cancer Res. 2012 May 1;18(9):2591-602. doi: 10.1158/1078-0432.CCR-11-1554. Epub 2012 Mar 5.

4.

Naphthol derivatives as TRPV1 inhibitors for the treatment of urinary incontinence.

Urbahns K, Yura T, Mogi M, Tajimi M, Fujishima H, Masuda T, Yoshida N, Moriwaki T, Lowinger TB, Meier H, Chan F, Madge D, Gupta JB.

Bioorg Med Chem Lett. 2011 Jun 1;21(11):3354-7. doi: 10.1016/j.bmcl.2011.04.013. Epub 2011 Apr 9.

PMID:
21531136
5.

Recent developments in the discovery of protein kinase inhibitors from the urea class.

Dumas J, Smith RA, Lowinger TB.

Curr Opin Drug Discov Devel. 2004 Sep;7(5):600-16. Review.

PMID:
15503863
6.

Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3: Orally active anti-inflammatory agents.

Murata T, Shimada M, Sakakibara S, Yoshino T, Masuda T, Shintani T, Sato H, Koriyama Y, Fukushima K, Nunami N, Yamauchi M, Fuchikami K, Komura H, Watanabe A, Ziegelbauer KB, Bacon KB, Lowinger TB.

Bioorg Med Chem Lett. 2004 Aug 2;14(15):4019-22.

PMID:
15225718
7.

Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 2: Improvement of in vitro activity.

Murata T, Shimada M, Kadono H, Sakakibara S, Yoshino T, Masuda T, Shimazaki M, Shintani T, Fuchikami K, Bacon KB, Ziegelbauer KB, Lowinger TB.

Bioorg Med Chem Lett. 2004 Aug 2;14(15):4013-7.

PMID:
15225717
8.

Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent.

Khire UR, Bankston D, Barbosa J, Brittelli DR, Caringal Y, Carlson R, Dumas J, Gane T, Heald SL, Hibner B, Johnson JS, Katz ME, Kennure N, Kingery-Wood J, Lee W, Liu XG, Lowinger TB, McAlexander I, Monahan MK, Natero R, Renick J, Riedl B, Rong H, Sibley RN, Smith RA, Wolanin D.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):783-6.

PMID:
14741289
9.

Discovery of novel and selective IKK-beta serine-threonine protein kinase inhibitors. Part 1.

Murata T, Shimada M, Sakakibara S, Yoshino T, Kadono H, Masuda T, Shimazaki M, Shintani T, Fuchikami K, Sakai K, Inbe H, Takeshita K, Niki T, Umeda M, Bacon KB, Ziegelbauer KB, Lowinger TB.

Bioorg Med Chem Lett. 2003 Mar 10;13(5):913-8. Erratum in: Bioorg Med Chem Lett. 2003 Oct 20;13(20):3627.

PMID:
12617920
10.

Design and discovery of small molecules targeting raf-1 kinase.

Lowinger TB, Riedl B, Dumas J, Smith RA.

Curr Pharm Des. 2002;8(25):2269-78. Review.

PMID:
12369855
11.

Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach.

Smith RA, Barbosa J, Blum CL, Bobko MA, Caringal YV, Dally R, Johnson JS, Katz ME, Kennure N, Kingery-Wood J, Lee W, Lowinger TB, Lyons J, Marsh V, Rogers DH, Swartz S, Walling T, Wild H.

Bioorg Med Chem Lett. 2001 Oct 22;11(20):2775-8.

PMID:
11591521
12.

1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.

Dumas J, Hatoum-Mokdad H, Sibley R, Riedl B, Scott WJ, Monahan MK, Lowinger TB, Brennan C, Natero R, Turner T, Johnson JS, Schoenleber R, Bhargava A, Wilhelm SM, Housley TJ, Ranges GE, Shrikhande A.

Bioorg Med Chem Lett. 2000 Sep 18;10(18):2051-4.

PMID:
10999468
13.

Discovery of a new class of p38 kinase inhibitors.

Dumas J, Sibley R, Riedl B, Monahan MK, Lee W, Lowinger TB, Redman AM, Johnson JS, Kingery-Wood J, Scott WJ, Smith RA, Bobko M, Schoenleber R, Ranges GE, Housley TJ, Bhargava A, Wilhelm SM, Shrikhande A.

Bioorg Med Chem Lett. 2000 Sep 18;10(18):2047-50.

PMID:
10999467
14.

Vicinal tetrahydrofuranyl substitution of alkyl chains. Tetra-, penta-, and hexafunctionalized arrays.

Paquette LA, Ohmori N, Lowinger TB, Rogers RD.

J Org Chem. 2000 Jul 14;65(14):4303-8.

PMID:
10891130
15.

Definition of Several Control Elements Relevant to the Stereodefined Serial Elaboration of Belted Poly(spirotetrahydrofurans) Fitted with a Cyclohexane Core.

Paquette LA, Stepanian M, Mallavadhani UV, Cutarelli TD, Lowinger TB, Klemeyer HJ.

J Org Chem. 1996 Oct 18;61(21):7492-7507.

PMID:
11667680
16.

Supplemental Content

Loading ...
Support Center